205 related articles for article (PubMed ID: 38109544)
21. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
Seshadri MR; Melnick AM
Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
[TBL] [Abstract][Full Text] [Related]
22. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.
Ho L; Davis RE; Conne B; Chappuis R; Berczy M; Mhawech P; Staudt LM; Schwaller J
Blood; 2005 Apr; 105(7):2891-9. PubMed ID: 15598810
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
24. Antiapoptotic properties of MALT1 protease are associated with redox homeostasis in ABC-DLBCL cells.
Zhu L; Tang F; Lei Z; Guo C; Song Y; Huang J; Xia X
Mol Carcinog; 2019 Dec; 58(12):2340-2352. PubMed ID: 31556968
[TBL] [Abstract][Full Text] [Related]
25. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis.
Mc Guire C; Elton L; Wieghofer P; Staal J; Voet S; Demeyer A; Nagel D; Krappmann D; Prinz M; Beyaert R; van Loo G
J Neuroinflammation; 2014 Jul; 11():124. PubMed ID: 25043939
[TBL] [Abstract][Full Text] [Related]
27. Detection of recombinant and cellular MALT1 paracaspase activity.
Nagel D; Krappmann D
Methods Mol Biol; 2015; 1280():239-46. PubMed ID: 25736752
[TBL] [Abstract][Full Text] [Related]
28. MALT1 auto-proteolysis is essential for NF-κB-dependent gene transcription in activated lymphocytes.
Baens M; Bonsignore L; Somers R; Vanderheydt C; Weeks SD; Gunnarsson J; Nilsson E; Roth RG; Thome M; Marynen P
PLoS One; 2014; 9(8):e103774. PubMed ID: 25105596
[TBL] [Abstract][Full Text] [Related]
29. The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.
Douanne T; Gavard J; Bidère N
J Cell Sci; 2016 May; 129(9):1775-80. PubMed ID: 27006117
[TBL] [Abstract][Full Text] [Related]
30. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
[TBL] [Abstract][Full Text] [Related]
31. T(14;18)(q32;q21) involving MALT1 and IGH genes in an extranodal diffuse large B-cell lymphoma.
Cook JR; Sherer M; Craig FE; Shekhter-Levin S; Swerdlow SH
Hum Pathol; 2003 Nov; 34(11):1212-5. PubMed ID: 14652825
[TBL] [Abstract][Full Text] [Related]
32. Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.
Jaworski M; Marsland BJ; Gehrig J; Held W; Favre S; Luther SA; Perroud M; Golshayan D; Gaide O; Thome M
EMBO J; 2014 Dec; 33(23):2765-81. PubMed ID: 25319413
[TBL] [Abstract][Full Text] [Related]
33. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling.
Elton L; Carpentier I; Staal J; Driege Y; Haegman M; Beyaert R
FEBS J; 2016 Feb; 283(3):403-12. PubMed ID: 26573773
[TBL] [Abstract][Full Text] [Related]
34. The paracaspase MALT1: biological function and potential for therapeutic inhibition.
Jaworski M; Thome M
Cell Mol Life Sci; 2016 Feb; 73(3):459-73. PubMed ID: 26507244
[TBL] [Abstract][Full Text] [Related]
35. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
36. Differential requirement for Malt1 in T and B cell antigen receptor signaling.
Ruland J; Duncan GS; Wakeham A; Mak TW
Immunity; 2003 Nov; 19(5):749-58. PubMed ID: 14614861
[TBL] [Abstract][Full Text] [Related]
37. Monoubiquitination and activity of the paracaspase MALT1 requires glutamate 549 in the dimerization interface.
Cabalzar K; Pelzer C; Wolf A; Lenz G; Iwaszkiewicz J; Zoete V; Hailfinger S; Thome M
PLoS One; 2013; 8(8):e72051. PubMed ID: 23977204
[TBL] [Abstract][Full Text] [Related]
38. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
39. Function and targeting of MALT1 paracaspase in cancer.
O'Neill TJ; Tofaute MJ; Krappmann D
Cancer Treat Rev; 2023 Jun; 117():102568. PubMed ID: 37126937
[TBL] [Abstract][Full Text] [Related]
40. Detection and measurement of paracaspase MALT1 activity.
Hailfinger S; Pelzer C; Thome M
Methods Mol Biol; 2014; 1133():177-88. PubMed ID: 24567102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
